推薦產品
等級
certified reference material
品質等級
形狀
liquid
特點
(Snap-N-Spike®)
包裝
ampule of 1 mL
製造商／商標名
Cerilliant®
濃度
1.0 mg/mL in acetonitrile
技術
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
應用
clinical testing
形式
single component solution
運輸包裝
dry ice
儲存溫度
−70°C
InChI
1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1
InChI 密鑰
HKVAMNSJSFKALM-GKUWKFKPSA-N
基因資訊
human ... FKBP1A(2280)
一般說明
以Zortress®、Certican和Afinitor®等商品名出售的依维莫司是一种免疫抑制剂，可用于防止器官移植排斥并治疗肾细胞癌和其他肿瘤。此认证加标溶液®适合用作从校准物、对照品或线性标准品的起始材料，通过LC/MS或GC/MS对患者全血样品中的依维莫司进行治疗性药物监测或临床和诊断检验。
應用
- Everolimus as a therapy for hepatoblastoma: Research demonstrates that Everolimus can induce autophagy-dependent ferroptosis in hepatoblastoma cells, highlighting its potential as a therapeutic agent in oncology research. This study provides insight into the mechanisms by which Everolimus can be utilized to target cancer cells through cell death pathways (Huang et al., 2024).
- Understanding oral mucosal injuries from mTOR inhibitors: A new hypothesis posits that oral mucosal injuries associated with mTOR inhibitors like Everolimus result from disruptions in cellular stress and apoptotic pathways. This study underscores the importance of understanding side effects in the context of targeted therapy for conditions such as cancers and immunosuppression (Sonis and Villa, 2023).
- Micellar formulation of Everolimus for neurological disorders: A stable micellar formulation of Everolimus (RAD001) has been developed for intracerebroventricular delivery, aimed at treating Alzheimer′s Disease and other neurological disorders. This formulation allows for direct brain administration, potentially enhancing the drug′s efficacy and safety profile (Gianessi et al., 2023).
- Pharmacokinetics in epilepsy treatment: The population pharmacokinetics of Everolimus were studied in patients with seizures associated with focal cortical dysplasia. This research aids in understanding the drug′s behavior in a specific neurological context, providing a foundation for dosing adjustments and therapeutic monitoring (Park et al., 2023).
法律資訊
Afinitor is a registered trademark of Novartis AG
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zortress is a registered trademark of Novartis AG
相關產品
產品號碼
描述
訂價
訊號詞
Danger
危險分類
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2
儲存類別代碼
3 - Flammable liquids
水污染物質分類（WGK）
WGK 2
閃點（°F）
35.6 °F - closed cup
閃點（°C）
2.0 °C - closed cup
客戶也查看了
Elisavet Paplomata et al.
Breast cancer research and treatment, 140(3), 453-462 (2013-08-03)
Everolimus is an orally available inhibitor of the mammalian target of rapamycin (mTOR), which has been approved in combination with exemestane for hormone receptor-positive (HR) breast cancer after failure of treatment with non-steroidal aromatase inhibitors. Everolimus is generally very well
Everolimus is a potent inhibitor of activated hepatic stellate cell functions in vitro and in vivo, while demonstrating anti-angiogenic activities.
Piguet AC, Majumder S, Maheshwari U, et al.
Clinical Science, 126(11), 775-784 (2014)
Hirohiko Yasui et al.
Cancer letters, 347(1), 114-122 (2014-02-05)
We examined efficacy of the mTOR inhibitor RAD001 to seek novel therapies for synovial sarcoma (SS). Although RAD001 had significant anti-tumor effects, its sensitivity differed among cell lines. Phospho-receptor tyrosine kinase (RTK) array analyses revealed c-MET phosphorylation in highly mTOR
Matteo Santoni et al.
Biochimica et biophysica acta, 1845(2), 221-231 (2014-02-01)
The mammalian target of rapamycin (mTOR) has emerged as an attractive cancer therapeutic target. Treatment of metastatic renal cell carcinoma (mRCC) has improved significantly with the advent of agents targeting the mTOR pathway, such as temsirolimus and everolimus. Unfortunately, a
Michael Cardamone et al.
The Journal of pediatrics, 164(5), 1195-1200 (2014-02-13)
To evaluate the efficacy and side effects of oral mammalian target of rapamycin (mTOR) inhibitors in children and adolescents with tuberous sclerosis complex (TSC) and intractable epilepsy or subependymal giant cell astrocytoma (SEGA). Single-center series of 13 children and adolescents
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務